

Adolfo Ferrando, MD, PhD

Institute for Cancer Genetics, Columbia University

Professor of Pediatrics and Pathology & Cell Biology

Associate Director for Research, Pediatric Oncology Division

Director Lymphoid Development and Malignancies Program, Herbert Irving Cancer Center

Adolfo Ferrando, MD, PhD, Institute for Cancer Genetics, Columbia University, is Professor of Pediatrics and Pathology & Cell Biology, Associate Director for Research in the Pediatric Oncology Division and Director of the Lymphoid Development and Malignancies Program at the Herbert Irving Comprehensive Cancer Center. Dr. Ferrando received his MD and PhD from the University of Oviedo in Spain and completed his postdoctoral training at Dana Farber Cancer Research Institute in Boston. Dr. Ferrando's research program combines genomics, biochemical, genetic and experimental therapeutics approaches towards the identification of novel therapies for the treatment of high risk leukemias and lymphomas. He has been the recipient of several honors and awards, most recently the Pershing Square Sohn Prize for Young Investigators in Cancer Research in 2014 and the V National "Doctores Diz Pintado" Cancer Research Prize in 2015. He is member the American Society of Clinical Investigation and currently serves in the editorial board of Leukemia and Cancer Research.

<http://ferrandolab.org/>

Recent relevant publications:

Dieck CL, Tzoneva G, Forouhar F, Carpenter Z, Ambesi-Impiombato A, Sánchez-Martín M, Kirschner Schwabe M, Lew S, Seetharaman J, Tong L and Ferrando AA. Structure and mechanisms of NT5C2 mutations driving thiopurine resistance in relapsed lymphoblastic leukemia. *Cancer Cell*. 2018; 34, 136–147.

Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabani H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, and Ferrando AA Clonal evolution mechanisms in NT5C2-mutant relapsed acute lymphoblastic leukemia. *Nature* 2018 553:511-514.